

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

**Safety Studies on Probiotic Strains *Lactobacillus*
rhamnosus HN001, *Lactobacillus acidophilus*
HN017, and *Bifidobacterium lactis* HN019**

A thesis submitted for the degree of Doctor of Philosophy
at Massey University, Palmerston North,
New Zealand

Joseph Shengli Zhou

2001

To my wife Lily, sons Punan and Daniel

Abstract

Lactic acid bacteria (LAB) have been consumed in foods by human beings for several centuries without any obvious adverse effects. But the safety of consumption of these organisms, especially novel strains, which are added to foods as probiotics, has been questioned recently due to occasionally reported infections implicated with some particular LAB strains. Evaluation of the safety or potential toxicity of probiotic candidate strains, especially novel strains for which no prior safety data exist, is highly recommended. The LAB strains *Lactobacillus rhamnosus* HN001 (DR20TM), *Lb. acidophilus* HN017 and *Bifidobacterium lactis* HN019 (DR10TM) are three newly identified probiotic organisms with immune-enhancing properties. Their safety/potential toxicity was investigated in this study through a series of both *in vitro* and *in vivo* experiments.

The mucus layer coating the surface of the gastrointestinal tract plays an important role in the gut mucosal defence system. Platelet activation and /or aggregation is a critical factor in the pathogenesis of infective endocarditis (IE). In the first part of this study, the potential pathogenicity of LAB strains was examined by *in vitro* mucin degradation (HN001, HN017, and HN019) and platelet aggregation (HN001 and HN019) assays. Following incubation with hog gastric mucin (HGM) in a minimal medium, the mucin degradation activity of test strains was determined via changes in the carbohydrate and protein concentration of the culture media and molecular weight changes of mucin glycoproteins (SDS-polyacrylamide gel electrophoresis, SDS-PAGE). The mucinolytic activity of test strains was also measured in an agarose petri dish assay. The results from these experiments suggested that HN001, HN017 and HN019 had no ability to degrade HGM *in vitro*. Flow cytometry analysis using platelet specific monoclonal antibodies demonstrated an inability of the test strains HN001 and HN019 to induce or enhance human platelet aggregation. These experiments indicated that the test strains are unlikely to degrade the mucin layer of the gastrointestinal mucosal surface or participate in the pathogenesis of endocarditis.

Resistance of LAB strains to commonly used antibiotics has caused safety concerns regarding the genetic stability of these resistance properties. The antibiotic

susceptibility and plasmid profiles of test organisms were investigated in another series of experiments. The susceptibility of the test strains to 18 antibiotics in common clinical use was examined by disk diffusion method. No extraordinary antimicrobial resistance was detected among the test strains (HN001, HN017, HN019, and HN067), and there were several antibiotics that efficiently suppressed the growth of test bacterial cells. A plasmid screening experiment demonstrated that all LAB strains examined were plasmid-free, this was verified by Southern blotting and DNA hybridisation techniques. These results indicate that the probiotic organisms tested here do not express or carry plasmid-associated antibiotic resistance, so their antibiotic resistance attributes are unlikely to disseminate to other clinically significant strains.

To investigate the oral toxicity of test strains (HN001, HN017, and HN019), conventional BALB/c mice were inoculated with a high dose (10^{11} cfu/mouse/day) of the test probiotic LAB strains for 8 consecutive days. The feed and water intake, body weight gain, and general health status, of the mice were monitored. The potential translocation of inoculated LAB strains and gut mucosal histological changes following feeding were also investigated. Random amplified polymorphic DNA (RAPD) fingerprinting techniques were used for bacterial identification. Results showed that the test LAB strains had no adverse effects on the parameters observed; no viable bacteria were recovered from blood or tissue samples (mesenteric lymph nodes, liver, and spleen). These results suggest that the test strains had no acute toxicity and had no potential to result in infection in normal mice at the high dose applied in this study.

To observe the consequences of longer-term consumption of test LAB strains, groups of BALB/c mice were orally administered with test LAB strains (HN001, HN017 and HN019) at doses of 5×10^7 , 10^9 or 5×10^{10} cfu/mouse/day for 4 weeks. In addition to the indicators observed in the acute toxicity study, the animals' haematological parameters; total and differential leucocyte counts; and blood biochemistry (plasma total protein, albumin, cholesterol, and glucose) were also investigated. Similar results to those of the acute toxicity study were obtained, i.e. 4 weeks consumption of HN001, HN017, and HN019 had no significant effects on the animals' general health status, haematology, blood biochemistry, or gut mucosal histological parameters. No dose-related effects were detected for any of the observed indicators. Translocation of test

LAB strains was not observed. These results suggest that longer-term consumption of test strains is unlikely to cause any obvious health problems in host animals.

In the final stage of this study, the potentially detrimental effects of HN001 and HN019 on hosts with sub-optimal immune functions were tested. To characterise the potential infectivity of test strains in immune deficient hosts, a group of adult male BALB/c mice pre-treated with dexamethasone (200µg/mouse/48 hrs) were fed with freshly cultured living HN001 or HN019 at doses of $1.5 \sim 2.5 \times 10^7$ cfu/mouse/day for 7 days; similar safety indicators to those outlined above were monitored. Results showed that no significant changes were noted in any of the safety parameters measured. No translocation of dietary LAB or systemic infection was detected. These findings suggest that HN001 and HN019 are well tolerated in immunocompromised mice without any significant safety concerns.

To investigate the effects of consumption of test LAB strains in hosts with a pre-existing immunological dysfunction, a group of female CBA/CaH mice (6 to 8 weeks) with experimentally induced autoimmune thyroiditis (EAT) were fed with freshly prepared probiotic preparations (HN001 4.2×10^8 cfu/mouse/day; HN019 2.16×10^8 cfu/mouse/day) for 5 to 8 weeks. Probiotic feeding was commenced one week prior to the immunization with auto antigens (MTg, mouse thyroglobulin). Antibody titres and spleen cell proliferative responses to the autoimmune inducing antigens (MTg) were determined via *in vitro* immunoassays. Lymphocyte (or mononuclear leucocyte) infiltration into thyroid tissue was also examined. Results showed that HN001 or HN019 feeding did not exacerbate spleen cell proliferative responses to MTg or lymphocyte infiltrations in thyroid tissues. These results indicate that feeding of HN001 or HN019 had no adverse effect on the induction or progress of autoimmune responses in CBA/CaH mice.

Overall, the combined results from these studies suggest that the probiotic LAB strains HN001, HN017, and HN019 are non-pathogenic for experimental animals and are likely to be safe for human consumption.

Acknowledgements

I wish to thank my chief supervisor Professor Harsharnjit Gill for providing much scientific, emotional and financial help throughout the course of these studies, for introducing me to scientific research and always believing that no problem was insurmountable. I also gratefully acknowledge the invaluable contribution of ideas and advice from my co-supervisors Dr Pramod Gopal and Dr Kay Rutherford.

I would like to thank a number of people for both their scientific contributions to this work, and their friendship over my time spent at Massey University: Dr Quan Shu, Dr Frank Cross, Ms Anne Broomfield, Miss Nicky Frearson, Ms Christine Booth, Miss Linley Fray, Mr Philip Moore, Miss Sarah Blackburn, Miss Kim Kennedy, Mr Daniel Johnson, Ms Fiona Doull, Miss Pauline Low, Ms Debbie Chesterfield, Ms Linda Ferry, Ms Jill Richards, Miss Fiona Hamilton, and Ms Nicky Rivers. I would also like to thank all other present and former members of Milk and Health Research Centre and the Small Animal Production Unit of Massey University, who have provided me with both technical assistance and friendly words of advice and encouragement over the years.

I gratefully acknowledge the considerable support given by research staff, particularly Dr Jaya Prasad, Dr Tim Coolbear and Dr Mark Lubbers, at the New Zealand Dairy Research Institute and for access to the laboratory facilities at the Microbiology, Nutrition, and Enzyme Section. Thanks also go to Garnett Davy for the preparation of some figures for this thesis. The histological work was conducted under the guidance of Mr Guy Hessel and Mr Mervyn Birtles in the Institute of Veterinary, Animal and Biomedical Science, Massey University.

I gratefully acknowledge financial support from the DNHP Mastorate Scholarship and MHRC Doctoral Scholarship from the Milk and Health Research Centre (Former Dairy Nutrition and Health Programme).

Finally, a special thanks to my wife Lily for her love, understanding, patience and support; special thanks also to my sons Punan and Daniel for the enjoyment they have brought to me.

Thank you all.

CONTENTS

ABSTRACT	i
ACKNOWLEDGEMENTS	iv
CONTENTS	v
LIST OF TABLES	xiii
LIST OF FIGURES	xiv
LIST OF ABBREVIATIONS	xvi
RELATED PUBLICATIONS	xx
CHAPTER 1 GENERAL INTRODUCTION	1
CHAPTER 2 LITERATURE REVIEW	5
2.1 Probiotics	5
2.2 Characterisation of probiotic strains	6
2.2.1 Host specificity	7
2.2.2 Viability	8
2.2.3 Adherence of LAB to GIT mucosal surface	9
2.3 Ecology of intestinal microflora	11
2.3.1 Development of intestinal microflora	11
2.3.2 Functions of the resident intestinal microflora	12
2.3.3 Modulation of intestinal microflora with probiotics	14
2.4 Established health effects and issues to be addressed	16
2.4.1 Improvement in lactose utilization	16
2.4.2 Preventive/therapeutic effect on diarrhoeal diseases	17
2.4.3 Immunomodulatory effects	18
2.4.4 Antimutagenic activities	20
2.4.5 Other health benefits	21
2.4.6 Issues	21
2.5 Safety of probiotics	23
2.5.1 History of safe use	23
2.5.2 Safety concerns about probiotics	23
2.5.2.1 Pathogenic potential of probiotics	24

2.5.2.2	Specific infections associated with LAB	26
2.5.2.3	Adverse metabolic activities	28
2.5.2.4	Adverse effects on the immune system	30
2.5.2.5	Transmission of antibiotic resistance genes	31
2.5.3	Published probiotic safety studies	32
2.5.4	Safety status of current commercial probiotics	36
2.5.5	Recommendations for probiotic safety assessment	37
2.5.5.1	Intrinsic properties	37
2.5.5.2	Pharmacokinetics	37
2.5.5.3	Acute or sub-acute oral toxicity studies	38
2.5.5.4	Dose-response studies	38
2.5.5.5	Adverse effects on the immune system	38
2.5.5.6	Studies in human volunteers	38
2.5.5.7	Epidemiological surveillance	38
2.5.6	Principles of safety studies	39
2.5.7	Food/health authorities' views on the safety of probiotics	40
2.6	Summary	40
CHAPTER 3	MATERIALS AND METHODS	42
3.1	Bacterial strains	42
3.2	Water supplies and sterilisation	42
3.3	Media preparation and storage	42
3.4	Common buffers and solutions	43
3.5	Growth, maintenance and storage of cultures	44
3.5.1	Anaerobic conditions	44
3.5.2	Bacterial cultivation	44
3.5.3	Storage of bacterial cultures	44
3.6	Experimental equipment	45
3.7	Mucin purification	45
3.8	SDS-PAGE	45
3.9	Staining of polyacrylamide gels	46

3.9.1	PAS staining	46
3.9.2	Coomassie blue staining	46
3.9.3	Silver staining	46
3.10	DNA extractions	47
3.11	PCR	47
3.12	PCR product purification	47
3.13	PCR product visualisation	48
3.14	Southern blotting & DNA hybridisation	48
3.15	Preparation of LAB cultures for inoculation in mice	49
3.16	Animals	49
3.17	Feeding of bacterial cultures in mice	49
3.18	Collection of blood and tissue samples	50
3.19	Bacterial translocation assay	51
3.20	Haematology	51
3.21	Histology	51
3.22	Measurement of protein concentration	52
3.23	Measurement of carbohydrate concentration	52
3.24	Measurement of total plasma cholesterol	52
3.25	Preparation of spleen cell suspensions	53
3.26	Preparation of peritoneal macrophages	53
3.27	ELISA for antibody assessment	54
3.28	Leucocyte phenotyping	54
3.29	Spleen cell proliferation assay	55
3.30	Blood leucocyte and peritoneal macrophage phagocytosis	56
3.31	Statistical analysis	56
CHAPTER 4	PROBIOTICS AND MUCIN DEGRADATION	58
	Abstract	58
4.1	Introduction	59
4.2	Materials and methods	60
4.2.1	Bacterial strains	60
4.2.2	Mucin degradation in broth medium	60
4.2.3	Measurement of total carbohydrate and protein concentrations	61

4.2.4	Calculation of mucin degradation	61
4.2.5	SDS-PAGE	62
4.2.6	Assessment of mucin degradation by petri dish assay	62
4.3	Results	62
4.3.1	Bacterial growth	62
4.3.2	Changes in total mucin carbohydrate and protein concentrations	63
4.3.3	SDS-PAGE analysis	63
4.3.4	Assessment of mucin degradation in petri dish	65
4.4	Discussion	66
CHAPTER 5	EFFECT OF HN001 AND HN019 ON HUMAN PLATELET AGGREGATION <i>IN VITRO</i>	70
	Abstract	70
5.1	Introduction	71
5.2	Materials and methods	72
5.2.1	Preparation of HN001, HN019, and <i>Lb. GG</i>	72
5.2.2	Chemicals and monoclonal antibodies	72
5.2.3	Collection and preparation of blood samples for platelet aggregation assays	73
5.2.4	Flow cytometry analysis	74
5.2.5	Haematology	75
5.3	Results	75
5.3.1	Platelet activation	75
5.3.2	Platelet aggregation	77
5.4	Discussion	79
CHAPTER 6	ANTIBIOTIC SUSCEPTIBILITY AND PLASMID PROFILES OF HN001, HN017, HN019 AND HN067	82
	Abstract	82
6.1	Introduction	83
6.2	Materials and methods	84

6.2.1	Probiotic strains HN001, HN017, HN019 and HN067	84
6.2.2	Media and antibiotics	85
6.2.3	Antibiotic susceptibility tests	86
6.2.4	Plasmid isolation	86
6.2.5	Southern blotting and DNA hybridisation	87
6.3	Results	88
6.3.1	Antibiotic susceptibility	88
6.3.2	Plasmid profiles	90
6.4	Discussion	92
CHAPTER 7 ACUTE ORAL TOXICITY OF PROBIOTIC STRAINS HN001, HN017, AND HN019		97
	Abstract	97
7.1	Introduction	98
7.2	Materials and methods	98
7.2.1	Probiotic strains	98
7.2.2	Animals	99
7.2.3	Experimental design	99
7.2.4	Bacterial translocation	99
7.2.5	Identification of translocated organisms	100
7.2.6	Histology	100
7.3	Results	101
7.3.1	General health status	101
7.3.2	Feed intake and growth rate	101
7.3.3	Histological changes	102
7.3.4	Bacterial translocation	103
7.4	Discussion	106
CHAPTER 8 TOLERANCE OF MICE TO FOUR WEEK FEEDING WITH PROBIOTIC STRAINS HN001, HN017, AND HN019		109
	Abstract	109
8.1	Introduction	110
8.2	Materials and methods	111

8.2.1	Animals	111
8.2.2	Probiotic strains	111
8.2.3	Experimental design	111
8.2.4	Haematology	111
8.2.5	Blood biochemistry	112
8.2.6	Bacterial translocation	112
8.2.7	Histology	112
8.3	Results	112
8.3.1	Feed and water intake	112
8.3.2	Growth	113
8.3.3	Haematology	114
8.3.4	Blood biochemistry	114
8.3.5	Histological changes	115
8.3.6	Bacterial translocation	116
8.4	Discussion	117
CHAPTER 9	SAFETY ASSESSMENT OF PROBIOTIC STRAINS HN001 AND HN019 IN IMMUNOCOMPROMISED MICE	120
	Abstract	120
9.1	Introduction	121
9.2	Materials and methods	122
9.2.1	Animals and immunosuppression	122
9.2.2	Probiotic strains	123
9.2.3	Bacterial translocation	123
9.2.4	Haematology	123
9.2.5	Immune responses	124
9.3	Results	124
9.3.1	General health status	124
9.3.2	Feed and water intakes and live weight changes	124
9.3.3	Haematological changes	125
9.3.4	Effect on health	126
9.3.5	Bacterial translocation	126
9.4	Discussion	131

CHAPTER 10	EFFECT OF FEEDING PROBIOTIC STRAINS HN001 AND HN019 ON EXPERIMENTAL AUTOIMMUNE THYROIDITIS	135
	Abstract	135
10.1	Introduction	136
10.2	Materials and methods	137
10.2.1	Preparation of mouse thyroglobulin	137
10.2.2	Animals	140
10.2.3	Feeding of probiotics	140
10.2.4	Induction of EAT	140
10.2.5	Autoantibody measurements	141
10.2.6	Spleen lymphocyte proliferative responses to MTg	141
10.2.7	Histology	141
10.3	Results	142
10.3.1	Clinical observations	142
10.3.2	Immune responses	142
10.3.3	Histological changes	144
10.4	Discussion	145
CHAPTER 11	GENERAL DISCUSSION	149
11.1	Overview	149
11.2	Aim	150
11.3	Safety of HN001, HN017, and HN019	150
11.3.1	Potential pathogenicity	151
11.3.1.1	Opportunistic infections	151
11.3.1.2	Potential adverse metabolic activities	152
11.3.2	Effect on autoimmune responses	154
11.3.3	Genetic stability	155
11.3.4	Toxicity / tolerance	156
11.4	Further studies	157
11.5	Conclusions	158
	BIBLIOGRAPHY	159
APPENDIX 1	Medium composition	185

APPENDIX 2	Common buffers and solutions	188
APPENDIX 3	Experimental equipment	191
APPENDIX 4	Mouse diet composition	194
APPENDIX 5	Peer-reviewed publications from this work	195

List of tables

Table 2.1	Selection criteria for probiotic microorganisms	7
Table 2.2	Classifications of probiotic organisms and their safety status	24
Table 3.1	Bacterial strains used in this study	43
Table 3.2	Mouse general health score scales	50
Table 4.1	Growth of LAB or faecal microflora in different culture media	63
Table 4.2	Degradation of mucin carbohydrates and proteins	64
Table 5.1	Reaction system for platelet aggregation test	73
Table 5.2	Platelet activation by probiotic strains	76
Table 6.1	Antibiotics used in experiments	85
Table 6.2	Antibiotic susceptibility profiles of test probiotics	89
Table 6.3	Susceptibility status of various antibiotics to test probiotics	90
Table 7.1	Changes in ileum mucosal architecture	103
Table 7.2	Changes in colon and caecum mucosal architecture	104
Table 7.3	Bacterial translocation to different tissues	104
Table 8.1	Effect of four week probiotic feeding on the haematological and biochemical parameters of mice	115
Table 8.2	Effect of four week probiotic feeding on spleen weight index of mice	116
Table 8.3	Gut mucosal histology measurements of mice fed with probiotics for four weeks	116
Table 8.4	Incidence of bacterial translocation in mice fed with probiotics for four weeks	117
Table 8.5	Incidence of bacterial translocation to different tissues	117
Table 9.1	Experimental design	122
Table 9.2	Bacterial translocation in mice receiving DEX and probiotics or <i>S. typhimurium</i>	130
Table 10.1	Thyroid pathological index	142
Table 10.2	Serum anti-MTg antibody levels (Delta OD, Mean \pm SEM)	144
Table 10.3	Incidence of EAT and histological changes in the thyroids of mice receiving probiotics	145

List of figures

Fig. 2.1	General scheme of the composition and health effects of predominant human faecal bacteria	13
Fig. 4.1	The defence function of mucus layer on the surface of GIT -a simplified representation	60
Fig. 4.2	SDS-12.5% polyacrlamide gel analysis of mucin glycoproteins (I)	64
Fig. 4.3	SDS-7.5% polyacrylamide gel analysis of mucin glycoproteins (II)	65
Fig. 4.4	Mucin degradation assay in agarose petri dish	66
Fig. 5.1	Platelet gating and analysis by flow cytometry	76
Fig. 5.2	Changes in platelet fluorescence profile following activation	77
Fig. 5.3	Fluorescence profiles of platelets incubated with test LAB strains	78
Fig. 5.4	Changes in light scattering profiles of activated platelets	79
Fig. 6.1	Agarose gel electrophoresis of “plasmid” DNA	91
Fig.6.2	Southern blotting and chromosomal DNA-DNA hybridisation	91
Fig. 6.3	Agarose gel electrophoresis of PCR product of chromosomal DNA probe	92
Fig.7.1	Daily feed intake of mice fed with probiotic LAB strains	101
Fig.7.2	Growth rate of mice fed with probiotic strains	102
Fig.7.3	Spleen weight index of mice fed with probiotic strains	103
Fig.7.4	RAPD patterns of strains recovered from animals fed with HN001	105
Fig.7.5	RAPD patterns of strains recovered from animals fed with HN017 or LA-1	105
Fig.7.6	RAPD patterns of strains recovered from animals fed with HN019	106
Fig.8.1	Daily feed intake of mice fed with probiotics for four weeks	113
Fig.8.2	Daily water intake of mice fed with probiotics for four weeks	113
Fig.8.3	Overall body weight gain of mice fed with probiotics for four weeks	114
Fig.9.1	Total feed intakes of mice receiving DEX and probiotics	125
Fig.9.2	Total water intakes of mice receiving DEX and probiotics	125
Fig.9.3	Changes in body weight of mice receiving DEX and probiotics	126
Fig.9.4	Haematological changes in mice administered DEX and probiotics	127
Fig.9.5	Total and differential blood leucocyte counts in mice administered DEX and probiotics	128

Fig.9.6	Spleen weight index in mice administered DEX and probiotics	129
Fig.9.7	Phagocytic cell activity of peripheral blood leucocytes from mice receiving DEX and probiotics	129
Fig.10.1	Separation of MTg from thyroid extracts	138
Fig.10.2	SDS-7.5% polyacrylamide gel analysis of MTg purified from mouse thyroid extracts	139
Fig.10.3	Changes in body weight during the period of probiotic feeding	143
Fig.10.4	Spleen weight indices of mice fed with probiotics for 7 weeks	143
Fig.10.5	Spleen cell proliferative responses to MTg	144

List of abbreviations

AAD	antibiotic associated diarrhoea
ACF	aberrant crypt foci
ACNFP	Government's Advisory Committee on Novel Foods and Processes
ADI	acceptable daily intake
ADP	adenosine 5' -diphosphate
AOM	azoxymethane
AKP	alkaline phosphatase
ATCC	American Type Culture Collection
AXN	alloxan
BALT	bronchus - associated lymphoid tissues
BBN	N-butyl-N- (4-hydroxybutyl) nitrosamine
BHI	brain and heart infusion
BSA	bovine serum albumin
BT	bacterial translocation
CFA	complete Freund's adjuvant
CFU	colony forming unit
CHO	carbohydrate
CI	cellular immunity
CT	computed tomography
CV	coefficient of variation
DEX	dexamethasone
DMH	1, 2-dimethylhydrazine
DTH	delayed type hypersensitivity
EAT	experimental autoimmune thyroiditis
Eh	redox potential
EH	epithelial cell height
EPN	epinephrine
FC	flow cytometry
FCS	foetal calf serum

FI	feed intake
FITC	fluorescein-isothiocyanate
FPLC	fast protein liquid chromatography
GALT	gut-associated lymphoid tissues
GCC	glucocorticosteroids
GCS	glucocorticoides
GF	germ free
GHS	general health score
GI	gastric intestine
GIT	gastrointestinal tract
GLM	general linear models (SAS programme)
GRAS	generally recognised as safe
H & E	haematoxylin and eosin
HB	haemoglobin
HGM	hog gastric mucin
HI	humoral immunity
HIG	human intestinal glycoprotein
HIV	human immunodeficiency virus
HN001	<i>Lactobacillus rhamnosus</i> HN001 (DR20™)
HN017	<i>Lactobacillus acidophilus</i> HN017
HN019	<i>Bifidobacterium lactis</i> HN019 (DR10™)
HN033/Lb. GG	<i>Lactobacillus rhamnosus</i> GG (Lb. GG)
HN067	<i>Lactobacillus rhamnosus</i> HN067
HRP	horseradish peroxidase
HT	haematocrit
IBS	irritable bowel syndrome
IE	infective endocarditis
IFA	incomplete Freund's adjuvant
IFN	interferon
JCA	juvenile chronic arthritis
KD	kilo Daltons
LAB	lactic acid bacteria
LD ₅₀	50% of lethal dose
LDL	low density lipoprotein

LM	lactose maldigestion
LPS	lipopolysaccharide
LWG	live weight gain
MAC	macrophages
MAF	macrophage activating factor
MALT	mucosal associated lymphoid tissues
MCH	mean corpuscular haemoglobin
MCHC	mean corpuscular haemoglobin concentration
MCV	mean corpuscular volume
2-ME	2-mercaptoethanol
MFI	mean fluorescence intensity
MHC	major histocompatibility complex
MIC	minimal inhibition concentration
MLN	mesenteric lymph node
MLS	macrolide-linocosamide-streptomgramin
MoAbs	monoclonal antibodies
MQ-H ₂ O	Milli-Q plus system purified water
MRS	Mann-Rogosa-Sharpe
MRS-C	MRS supplemented with cysteine-HCl
MT	mucosal thickness
MT _g	mouse thyroglobulin
NCCLS	National Committee for Clinical Laboratory Standards
NCTC	National Collection of Type Cultures (UK)
NK	natural killer
NMS	normal mouse serum
NOD	non-obese diabetes
ODC	ornithine decarboxylase
OECD	Organisation for Economic Co-operation and Development
PAS	periodic acid-Schiff
PBL	peripheral blood lymphocytes
PBS	phosphate buffered saline
PBS-T	PBS supplemented with tween-20
PCR	polymerase chain reaction
PCV	packed cell volume

PE	phycoerythrin
PEC	peritoneal exudate cells
PGE	prostaglandin E
PI	pathological index
PLC	platelet count
PRO	protein
PRP	platelet rich plasma
PTg	porcine thyroglobulin
RAPD	random amplified polymorphic DNA finger-printing
RBC	red blood cells
RT	room temperature
SALT	skin - associated lymphoid tissues
S.C.	subcutaneous
SDS-PAGE	sodium dodecyl sulphate-polyacrylamide gel electrophoresis
SGR	specific growth rate
SHIME	simulator of the human intestinal microbial ecosystem
SI	sucrose-isomaltase deficiency
SLE	systemic lupus erythematosus
SMP	skim milk powder
SPF	specific pathogen free
SRBC	sheep red blood cells
SWI	spleen weight index
TD	traveller's diarrhoea
TNF	tumour necrosis factor
TPO	thyroperoxidase
VH	villus height
VLDL	very low density lipoprotein
WBC	white blood cells
WI	water intake

Related publications and conference presentations

- Acute oral toxicity and bacterial translocation studies on potentially probiotic strains of lactic acid bacteria, *Food and Chemical Toxicology* 2000, 38, 153-161.
- Potential probiotic lactic acid bacteria *Lactobacillus rhamnosus* (HN001), *Lactobacillus acidophilus* (HN017) and *Bifidobacterium lactis* (HN019) do not degrade gastric mucin *in vitro*, *International Journal of Food Microbiology* 2001, 63 (1-2), 81-89.
- Safety assessment of potential probiotic lactic acid bacterial strains *Lactobacillus rhamnosus* HN001, *Lb. acidophilus* HN017, and *Bifidobacterium lactis* HN019 in BALB/c mice, *International Journal of Food Microbiology* 2000, 56, 87-96.
- Probiotic lactic acid bacteria (*Lactobacillus acidophilus* HN017, *Lb. rhamnosus* HN001 and *Bifidobacterium lactis* HN019) have no adverse effects on the health of mice, *International Dairy Journal* 2000, 9, 831-836 (co-author).
- *Lactobacillus rhamnosus* HN001, *Bifidobacterium lactis* HN019, and *Lactobacillus acidophilus* HN017 do not degrade gastric mucin *in vitro*. In: “Dairy Foods in Health” (Abstract Book), International Dairy Federation Nutrition Week, Wellington, New Zealand, March 1998, pp 24.
- Toxicity and dose-response studies of potential probiotic bacterial strains in mice (oral presentation), Probiotics—The Good Millennium BUGs Symposium. Sydney, Australia, August 12 –13, 1999 (Awarded “Best Student Presentation Award”).
- Antibiotic susceptibility profiles and plasmid mapping of potential probiotic bacterial strains, IXth International Congress of Bacteriology & Applied Microbiology, Sydney, Australia, August 16 – 20, 1999, ppBPO3.06.

- *In vivo* evidence: DR10 and DR20 are safe probiotic strains, IXth International Congress of Bacteriology & Applied Microbiology, Sydney, Australia, August 16 – 20, 1999, pp BPO3.07.
- *In vitro* and *in vivo* safety assessment of probiotic lactic acid bacterial strains, Sixth Symposium of Lactic Acid Bacteria, Veldhoven, The Netherlands, September 19-23, 1999, ppJ43.
- Evaluation of safety profiles of probiotic lactic acid bacterial strains *Lactobacillus rhamnosus* HN001 (DR20TM), *Lactobacillus acidophilus* HN017, and *Bifidobacterium lactis* HN019 (DR10TM), In: A.C.J. Tuijtelars, R.A. Samson, F.M. Rombouts & S. Notermans (editors), Food Microbiology and Food Safety into the Next Millennium. Proceedings of the Seventeenth International Symposium of the International Committee on Food Microbiology and Hygiene (ICFMH), Veldhoven, The Netherlands, October 1999, pp 877-881.
- *Bifidobacterium lactis* HN019 enhances host immunity and resistance to gastrointestinal pathogens. In: A.C.J. Tuijtelars, R.A. Samson, F.M. Rombouts & S. Notermans (editors), Food Microbiology and Food Safety into the Next Millennium. Proceedings of the Seventeenth International Symposium of the International Committee on Food Microbiology and Hygiene (ICFMH), Veldhoven, The Netherlands, October 1999, pp 858-861.
- Establishment of an immunocompromised murine model in BALB/c mice, Australasian Society for Immunology Annual Meeting, University of Otago, New Zealand, December 5-8, 1999. pp7.9.
- *Bifidobacterium lactis* HN019 enhances antibody responses against *Escherichia coli* K-88 in piglets, Australasian Society for Immunology Annual Meeting, University of Otago, New Zealand, December 5-8, 1999, pp10.2.
- Bacterial translocation in immune-compromised mice following oral feeding of probiotic lactic acid bacteria, Microbiology Beyond 2000—The New Zealand

Microbiological Society Inc, University of Otago, New Zealand, November 23-26, 1999, pp p39.

- Investigation of the Potential Association of Probiotic LAB Strains *Lactobacillus rhamnosus* HN001 and *Bifidobacterium lactis* HN019 with Platelet Aggregation, International Congress of Probiotics Medicine, Los Angeles, California, July 6 to 8, 2001.
- Probiotic lactic acid bacteria have no oral toxicity in autoimmune mice, 9th International Congress of Toxicology, Brisbane, 8-12 July 2001.